parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in astrocytes (4013 nCPM)	1.00
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 6024

CTNND2 in astrocytes, braak+0.78 (p 0.014) → -0.40 (p 0.287)receipt 6030
CTNND2 in dopamine neurons, braak-0.25 (p 0.518) → -0.29 (p 0.456)receipt 6031

receipt 6031: CTNND2 in dopamine neurons, braak

power: full sample -0.26 (p 0.289, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.28 (p 0.261, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.125, n 18). could be the mix.
skeptic: leave-one-out range -0.34 to -0.17, sign flips 0; without severely affected donors -0.26 (p 0.289, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTNND2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6030: CTNND2 in astrocytes, braak

power: full sample +0.10 (p 0.702, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.08 (p 0.761, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.26, sign flips 1; without severely affected donors +0.10 (p 0.702, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTNND2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts